IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients

Journal of Medical Virology

Volumn 81, Issue 8, 2009, Pages 1412-1421

  Ayadi, Wajdi ^a,b   Karray Hakim, Héla ^a   Feki, Lamia ^a   Khabir, Abdelmajid ^a   Boudawara, Tahia ^a   Ghorbel, Abdelmonem ^a   Daoud, Jamel ^a   Frikha, Mounir ^a   Hammami, Adnane ^a  

^a Hopital Habib Bour guiba   (Tunisia)

^b UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Antibodies; Diagnosis; EBNA1; EBV; Nasopharyngeal carcinoma

Indexed keywords

BIOLOGICAL MARKER; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; INFORMED CONSENT; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PATIENT INFORMATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; SERODIAGNOSIS; SEROLOGY; TUNISIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; CARCINOMA; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUNISIA; YOUNG ADULT;

HUMAN HERPESVIRUS 4;

EID: 68049084700     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21532     Document Type: Article

References (39)

1. Ambinder RF, MullenM, Chang YN, Hayward GS, Hayward SD. 1991. Functional domains of Epstein-Barr virus nuclear antigen EBNA- 1. J Virol 65:1466-1478.
2. Ayadi W, Feki L, Khabir A, Boudawara T, Ghorbel A, Charfeddine I, Daoud J, Frikha M, Hammami A, Karray-Hakim H. 2007. Polymorphism analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from Tunisian patients. Virus Genes 34: 137-145. (Pubitemid 46411980)
3. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. 2005. Pathology and genetics of head and neck tumors (World Health Organization classification of tumors). Lyon, France: IARC Press. 430pp.
4. Benider A, Sahraoui S, Acharki A, Samlali R, Kahlain A. 1995. Carcinomas of the nasopharynx in children. Analysis of 50 cases. Bull Cancer 82:155-161.
5. Boualga K, Ghouadni R. 1984. Carcinoma of the nasopharynx in Algeria. Apropos of a series of 213 cases. Ann Radiol 27:621-628.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Chen MR, Yang JF, Hsu TY, Liu MY, Chen JY, Yang CS. 1996. Use of bacterially expressed GST/EBNA-1 fusion proteins for detection of antibodies in sera from patients with nasopharyngeal carcinoma and healthy donors. Chin J Microbiol Immunol 29:65-79.
8. Chen MR, Liu MY, Hsu SM, Fong CC, Chen CJ, Chen IH, Hsu MM, Yang CS, Chen JY. 2001. Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients. J Med Virol 64:51-57.
9. Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ, Lu SN, Liu HW. 2005. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: Case control studies. J Rheumatol 32:44-47.
10. Cheng HM, Foong YT, Mathew A, Sam CK, Dillner J, Prasad U. 1993. Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen,EBNA1:Acomplementary test to the IgA/VCA immunofluorescence assay. J Virol Methods 42:45-51. (Pubitemid 223039397)
11. Dardari R, Khyatti M, Benider A, Jouhadi H, Kahlain A, Cochet C, Mansouri A, El Gueddari B, Benslimane A, Joab I. 2000. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int J Cancer 86:71-75. (Pubitemid 30133989)
12. Dardari R, Hinderer W, Lang D, Benider A, El Gueddari B, Joab I, BenslimaneA, Khyatti M.2001. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: Complementary test of ZEBRA protein and early antigens p54 and p138. J Clin Microbiol 39:3164-3170. (Pubitemid 32830309)
13. DardariR,Menezes J, Drouet E, Joab I, BeniderA,Bakkali H, Kanouni L, Jouhadi H, Benjaafar N, El Gueddari B, Hassar M, Khyatti M. 2008. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. J Clin Virol 41:96-103. (Pubitemid 351187888)
14. de Sanjosé S, Bosch R, Schouten T, Verkuijlen S, Nieters A, Foretova L, Maynadié M, Cocco PL, StainesA,Becker N, BrennanP, Benavente Y, Boffetta P, Meijer CJ, Middeldorp JM. 2007. Epstein-Barr virus infection and risk of lymphoma: Immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. Int J Cancer 121:1806-1812. (Pubitemid 47417301)
15. de-Vathaire F, Sancho-Garnier H, de-Thé H, PieddeloupC, Schwaab G, Ho JH, Ellouz R, Micheau C, Cammoun M, Cachin Y. 1988. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int J Cancer 42:176-181.
16. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM. 2004. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: A comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190:53-62. (Pubitemid 38858404)
17. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM. 2006. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: Options for field screening. J Clin Microbiol 44:1459-1467.
18. Fahraeus R, Fu LH, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, YadavM, Busson P, Tursz T, Kallin B. 1988. Expression of Epstein-Barr virus encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42:329-338. (Pubitemid 18229982)
19. Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W, Prasad U. 1990. Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 45:1061-1064. (Pubitemid 20201576)
20. Greiner M, Sohr D, Gobel P. 1995. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods 185:123-132.
21. Henle G, Henle W. 1976. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17:1-7.
22. Ho HC, Ng MH, Kwan HC, Chau JC. 1976. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 34:655-660.
23. Hsu MM, Huang SC, Lynn TC, Hsieh T, Tu SM. 1982. The survival of patients with nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 90:289-295.
24. Hsu MM, Hsu WC, Sheen TS, Kao CL. 2001. Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 26:334-338.
25. Hu B, Hong G, Li Z, Xu J, Zhu Z, Li L. 2007. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma. Biotechnol Appl Biochem 47:59-69. (Pubitemid 46762273)
26. Karray H, Ayadi W, Fki L, Hammami A,Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM. 2005. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 75:593-602. (Pubitemid 40293528)
27. Khabir A, Karray H, Rodriguez S, Rosé M, Daoud J, Frikha M, Boudawara T, Middeldorp J, Jlidi R, Busson P. 2005. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2:39.
28. Khanfir A, Frikha M, Ghorbel A, Drira MM, Daoud J. 2007. Prognostic factors in metastatic nasopharyngeal carcinoma. Cancer/Radiothérapie 11:461-464. (Pubitemid 350236876)
29. Liu MY, Huang YT, Sheen TS, Chen JY, Tsai CH. 2004. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma. J Med Virol 73:574-582. (Pubitemid 38857208)
30. Lu JJ, Chen DY, Hsieh CW, Lan JL, Lin FJ, Lin SH. 2007. Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. Lupus 16:168-175. (Pubitemid 46506593)
31. MacKenzie J, Gray D, Pinto-Paes R, Barrezueta LF, Armstrong AA, Alexander FA, McGeoch DJ, Jarrett RF. 1999. Analysis of Epstein-Barr virus (EBV) nuclear antigen 1 subtypes in EBV-associated lymphomas from Brazil and the United Kingdom. J Gen Virol 80:2741-2745. (Pubitemid 29458637)
32. Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM. 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBVassociated diseases. J Infect Dis 179:1108-1115. (Pubitemid 29196489)
33. Middeldorp JM, Herbrink P. 1988. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 21:133-146. (Pubitemid 18234286)
34. Niedobitek G, Young LS. 1994. Epstein-Barr virus persistence and virus-associated tumours. Lancet 343:333-335. (Pubitemid 124000790)
35. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM. 2007. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 79:1710-1721. (Pubitemid 47479889)
36. Sandvej K, Zhou XG, Hamilton-Dutoit S. 2000. EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: Evidence for geographical polymorphism but not for tumourspecific subtype restriction. J Pathol 191:127-131. (Pubitemid 30394888)
37. van Grunsven WM, Nabbe A,Middeldorp JM. 1993. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 40:161-169.
38. Yates J, Warren N, Reisman DSB. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81:3806-3810. (Pubitemid 14087807)
39. Zhang XS, Wang HH, Hu LF, Li A, Zhang RH, Mai HQ, Xia JC, Chen LZ, Zeng YX. 2004. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Lett 211:11-18. (Pubitemid 38759764)